Abstract | BACKGROUND:
Lipid-lowering is effective in the prevention of cardiovascular morbidity and mortality in patients with coronary artery disease, but effective strategies for improving the implementation of these therapies are needed. METHODS: In the 10,288 patients in the OPUS-TIMI 16 trial, patients were stratified by use of lipid-lowering therapy during index hospitalization and were compared for use of lipid-lowering therapy at follow-up as well as for clinical outcomes. RESULTS:
Lipid-lowering therapy was used in 38% of patients during the index hospitalization, of which 94% were statins. At 10 months, 88% of patients who were discharged on lipid-lowering medications remained on these drugs. Conversely, only 34% of patients not discharged on lipid-lowering medications were receiving them at 10 months. Forty-one percent of patients with prior history of hyperlipidemia requiring treatment were not discharged on lipid-lowering therapy, and of these, only 51% were subsequently started on a lipid-lowering medication as an outpatient despite clear indications. Patients treated as inpatients with lipid-lowering therapy had a lower mortality rate at 10 months adjusted by propensity analysis (3.1% vs 5.1%, P < .0001) than patients not treated with lipid-lowering therapy. CONCLUSION:
|
Authors | Charles S Smith, Christopher P Cannon, Carolyn H McCabe, Sabina A Murphy, Jane Bentley, Eugene Braunwald |
Journal | American heart journal
(Am Heart J)
Vol. 149
Issue 3
Pg. 444-50
(Mar 2005)
ISSN: 1097-6744 [Electronic] United States |
PMID | 15864232
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
Topics |
- Acute Disease
- Aged
- Coronary Disease
(complications, mortality, therapy)
- Female
- Follow-Up Studies
- Guideline Adherence
- Heart Failure
(complications, diagnosis)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Hyperlipidemias
(complications, prevention & control)
- Male
- Middle Aged
- Patient Compliance
- Survival Rate
- Syndrome
|